ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)

JazzIRT/E+ via Getty Images ClearPoint's (NASDAQ:CLPT) business is beginning to gather pace, with a period of heavy investment starting to pay off. The last time I wrote about ClearPoint I suggested that progress in the business had yet to be reflected in the share price. This is starting to happen now though, with the stock up over 70% since then. uniQure's strong Phase I/II clinical trial data and ClearPoint's solid Q2 results have been catalysts for this. I continue to think that ClearPoint is undervalue ...